iShares 20 Plus Year Treasury Bond ETF vs Vir Biotechnology Inc. Common Stock — how do they compare? iShares 20 Plus Year Treasury Bond ETF trades at $79.94 (market cap $48.65B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 27× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 20 Plus Year Treasury Bond ETF for 83 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| TLT | VIR | |
|---|---|---|
Market Cap | $48.65B | $1.80B |
Volume | 29,149,160 | 1,782,836 |
Sector | Fixed Income | Health |
52-Week High | $92.06 | $11.78 |
52-Week Low | $77.11 | $5.12 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | — | $1.36B |
Signals from Pluang's Aura AI — not financial advice
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $78.89, up 1.08% on the day but remains in a prolonged downtrend, having fallen 46% over five years. Technical indicators are bearish overall, with moving averages and oscillators signaling selling pressure. The fund continues to face headwinds from rising Treasury yields, which recently hit multi-decade highs, though recent PCE data provided some relief.
The outlook for TLT hinges on the direction of long-term interest rates. While current yields near 5.3% offer attractive income, further rate increases could pressure prices lower. Key risks include persistent inflation and Fed policy uncertainty. Investors should weigh high yield against potential capital depreciation in a rising rate environment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →